Gastro-oesophageal reflux disease in general practice. Last year's guidelines are probably biased.
作者信息
Waldum Helge L, Brenna Eiliv
出版信息
BMJ. 2002 Feb 23;324(7335):485-6.
Abstract
摘要
相似文献
1
Gastro-oesophageal reflux disease in general practice. Last year's guidelines are probably biased.
BMJ. 2002 Feb 23;324(7335):485-6.
2
Emerging drugs for gastro-oesophageal reflux disease.
Expert Opin Emerg Drugs. 2005 May;10(2):457-71. doi: 10.1517/14728214.10.2.457.
3
Comparative study of characteristics and disease management between subjects with frequent and occasional gastro-oesophageal reflux symptoms.
Aliment Pharmacol Ther. 2006 Mar 1;23(5):607-16. doi: 10.1111/j.1365-2036.2006.02811.x.
4
Gastro-oesophageal reflux disease--impact of guidelines on GP management.
Aust Fam Physician. 2008 Jan-Feb;37(1-2):73-7.
5
Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
Aliment Pharmacol Ther. 2005 Jun;21 Suppl 2:2-9. doi: 10.1111/j.1365-2036.2005.02467.x.
6
Impact of referral for gastro-oesophageal reflux disease on the workload of an academic Gastroenterology Unit.
Dig Liver Dis. 2005 Oct;37(10):735-40. doi: 10.1016/j.dld.2005.04.025.
7
[Medication therapeutic strategies for gastro-esophageal reflux disease].
Z Gastroenterol. 2007 Nov;45(11):1169-79. doi: 10.1055/s-2007-963531.
8
Sleep disturbances associated with gastro-oesophageal reflux disease: prevalence and impact of treatment in French primary care patients.
Dig Liver Dis. 2011 Oct;43(10):784-7. doi: 10.1016/j.dld.2011.06.004. Epub 2011 Jul 12.
9
Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Aliment Pharmacol Ther. 2004 Sep 15;20(6):637-43. doi: 10.1111/j.1365-2036.2004.02127.x.
10
Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Aliment Pharmacol Ther. 2005 Jun;21 Suppl 2:10-8. doi: 10.1111/j.1365-2036.2005.02468.x.
本文引用的文献
1
Blood, urine, stool, breath, money, and Helicobacter pylori.
Gut. 2001 Mar;48(3):287-9. doi: 10.1136/gut.48.3.287.
2
Management of gastro-oesophageal reflux disease in general practice.
BMJ. 2001 Feb 10;322(7282):344-7. doi: 10.1136/bmj.322.7282.344.
3
Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group.
BMJ. 2000 Sep 16;321(7262):659-64. doi: 10.1136/bmj.321.7262.659.
4
Treating non-ulcer dyspepsia and H pylori.
BMJ. 2000 Sep 16;321(7262):648-9. doi: 10.1136/bmj.321.7262.648.
5
Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group.
Lancet. 2000 May 13;355(9216):1665-9. doi: 10.1016/s0140-6736(00)02236-4.
6
An evidence-based appraisal of reflux disease management--the Genval Workshop Report.
Gut. 1999 Apr;44 Suppl 2(Suppl 2):S1-16. doi: 10.1136/gut.44.2008.s1.
7
Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion?
Aliment Pharmacol Ther. 2000 Mar;14(3):267-71. doi: 10.1046/j.1365-2036.2000.00750.x.
8
Personal review: is profound acid inhibition safe?
Aliment Pharmacol Ther. 2000 Jan;14(1):15-22. doi: 10.1046/j.1365-2036.2000.00681.x.
Zotero 插件